Zai Lab Ltd
$ 17.15
0.35%
02 Jun - close price
- Market Cap 1,843,181,000 USD
- Current Price $ 17.15
- High / Low $ 17.30 / 16.30
- Stock P/E N/A
- Book Value 6.47
- EPS -1.70
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.24 %
- 52 Week High 44.34
- 52 Week Low 15.96
About
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Analyst Target Price
$33.78
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-07 |
| Reported EPS | -0.46 | -0.46 | -0.33 | -0.37 | -0.45 | -0.8 | -0.42 | -0.82 | -0.5 | -0.98 | -0.71 | -1.25 |
| Estimated EPS | -0.2909 | -0.42 | -0.28 | -0.42 | -0.55 | -0.6333 | -0.78 | -0.73 | -0.92 | -0.87 | -1.03 | -0.81 |
| Surprise | -0.1691 | -0.04 | -0.05 | 0.05 | 0.1 | -0.1667 | 0.36 | -0.09 | 0.42 | -0.11 | 0.32 | -0.44 |
| Surprise Percentage | -58.1299% | -9.5238% | -17.8571% | 11.9048% | 18.1818% | -26.3224% | 46.1538% | -12.3288% | 45.6522% | -12.6437% | 31.068% | -54.321% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.67 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZLAB
2026-06-02 07:12:44
Zai Lab Ltd (ZLAB) shares are trading below recent analyst expectations on Nasdaq after the biotech company reported its Q1 2026 results in May. Despite posting a narrower loss per share (USD -0.46 vs. forecast USD -0.53) and revenue of USD 99.61 million, investor focus is now shifting towards the next estimated earnings release in August. The stock closed at USD 17.69 on May 29, 2026, significantly below the average 12-month price target from Wall Street analysts.
2026-06-01 17:39:41
Zai Lab (ZLAB) has experienced recent share price weakness, with the stock down 4.3% over the past day and 17.9% over the past month. Despite a current trading price of US$17.69, analysts suggest a potential intrinsic discount of 77.7% and a "fair value" of US$35.34, making it appear undervalued based on its pipeline and revenue potential. However, this optimistic outlook is tempered by risks related to China's pricing and reimbursement policies, as well as ongoing competition.
2026-05-29 18:40:13
This document provides a company profile and introduction for Zai Lab. It outlines key information about the company's operations, objectives, and market positioning. Further details on Zai Lab's strategic focus and business model are also included.
2026-05-29 11:08:44
Zai Lab Ltd's shares traded steadily on Nasdaq, with investors focusing on the company's late-stage oncology and autoimmune portfolio and its current valuation. The China-based biopharmaceutical company offers exposure to innovative cancer and autoimmune therapies for the Chinese and broader Asia-Pacific markets. Investor assessment hinges on the risk-reward profile, future cash generation, clinical milestones, and regulatory approvals rather than short-term price swings.
2026-05-29 07:40:44
Zai Lab's Chairperson and CEO, Du Ying, gifted a total of 107,700 American Depositary Shares (ADSs) to trusts established for the benefit of an adult son on May 26 and 27, 2026. These were bona fide gifts with no monetary value exchanged, and each ADS represents ten Ordinary Shares. Following these transactions, Du Ying retains a substantial direct ownership of 1,158,583 ADSs in the company.
2026-05-25 06:10:29
Zai Lab (ZLAB) shares dropped 9.6% following a leadership reshuffle, which saw President and COO Josh Smiley depart, and despite receiving FDA Fast Track Designation for its investigational drug, zoci, in extrapulmonary neuroendocrine carcinomas. The article examines how these events impact Zai Lab's investment narrative, emphasizing that while the Fast Track status strengthens zoci's potential as a key catalyst, significant risks remain concerning high R&D and SG&A expenditures. Investor evaluations diverge, with some analysts projecting higher revenue and earnings by 2028 compared to consensus forecasts, highlighting differing views on the company's future.
